• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Esaote, Hitachi forge ultrasound alliance

Article

Ultrasound developer Esaote, based in Genoa, Italy, has signed a letter of intent for a three-year technical and commercial cooperation agreement with Hitachi Medical. Pending regulatory approvals, the two firms will collaborate on new ultrasound

Ultrasound developer Esaote, based in Genoa, Italy, has signed a letter of intent for a three-year technical and commercial cooperation agreement with Hitachi Medical. Pending regulatory approvals, the two firms will collaborate on new ultrasound products and exchange technical information and components. Each company will continue to independently develop and market its existing product lines.

Both firms highlighted new ultrasound units at December’s RSNA conference. Esaote introduced Technos, a premium ultrasound device designed for abdominal, ob/gyn, vascular, small parts, breast, and urology imaging, while Tarrytown, NY-based Hitachi unveiled Hitachi 6000, a work-in-progress unit that includes tissue harmonic imaging, directional CFA, and artifact suppression algorithms (SCAN 12/15/99 and 1/12/00).

In other Esaote news, the company released preliminary financial results for fiscal year 1999 (end-December), posting consolidated sales of $196.8 million, up 11% from 1998’s $176.2 million. Sales in dedicated MRI climbed more than 60%, from $13.5 million in 1998 to $21.5 million in 1999, while the company’s ultrasound sales were $112.7 million, up from $106.6 million the year before.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.